适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A study to characterise the safety, tolerability and efficacy of LY4170156 in subjects with advanced solid tumorsCTIS2024-511238-11-00Eli Lilly & Co.216
进行中（未招募）
1 期
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid TumorsCTIS2023-509867-26-00Eli Lilly & Co.112
进行中（未招募）
1 期
A first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of three dose levels of the OVX033 vaccine, after intramuscular administration in healthy subjects aged 18-49 yearsCTIS2023-506396-94-00Osivax48
进行中（未招募）
1 期
A SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF REPEAT DOSES OF ARM210 IN HEALTHY SUBJECTS.Cardiac arrhythmiasMedDRA version: 20.0Level: HLGTClassification code: 10007521Term: Cardiac arrhythmias Class: 10007541CTIS2023-509086-20-00Armgo Pharma Inc.8
进行中（未招募）
1 期
Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.CTIS2023-509210-10-00niversitair Medisch Centrum Utrecht24